Insmed Incorporated Revenue and Competitors

Claim your profile

Bridgewater, NJ USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Insmed Incorporated's estimated annual revenue is currently $173.8M per year.(i)
  • Insmed Incorporated received $437.3M in venture funding in January 2018.
  • Insmed Incorporated's estimated revenue per employee is $217,459
  • Insmed Incorporated's current valuation is $2.8B. (January 2022)

Employee Data

  • Insmed Incorporated has 799 Employees.(i)
  • Insmed Incorporated grew their employee count by 13% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$10.9M70-3%N/AN/A
#2
$12.7M8215%N/AN/A
#3
$100.9M46517%N/AN/A
#4
$14.7M10418%$206.4MN/A
#5
$492.2M175212%$568MN/A
#6
$5M78-8%N/AN/A
#7
$3.5M35-8%$33.5MN/A
#8
$2M1318%N/AN/A
#9
$40.5M2615%N/AN/A
#10
$7.5M28-12%$38.7MN/A

Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company is dedicated to developing and bringing to market therapies that make a real difference in patients lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. Headquartered in Bridgewater, NJ, we are a rapidly growing company with offices in seven countries.

keywords:Biotechnology,Healthcare,Pharmaceuticals

N/A

Total Funding

799

Number of Employees

$173.8M

Revenue (est)

13%

Employee Growth %

$2.8B

Valuation

N/A

Accelerator

Insmed Incorporated News

2022-04-19 - Insmed (INSM) Scheduled to Post Earnings on Thursday

Goldman Sachs Group Inc. now owns 463,326 shares of the biopharmaceutical company's stock valued at $12,621,000 after purchasing an additional...

2022-04-17 - $53.63 Million in Sales Expected for Insmed Incorporated ...

Brokerages expect Insmed Incorporated (NASDAQ:INSM – Get Rating) to announce sales of $53.63 million for the current quarter,...

2022-03-30 - Insmed Reports Inducement Grants Under NASDAQ Listing ...

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.

2021-10-28 - Insmed Reports Third Quarter 2021 Financial Results and Provides Business Update

BRIDGEWATER, N.J., Oct. 28, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2021 and provided a bu ...

2021-05-19 - Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference

BRIDGEWATER, N.J., May 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from a total of nine posters and oral presentations across its three program ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$210.4M835N/AN/A
#2
$421.5M9070%$200M
#3
$300M104639%N/A
#4
$483.4M1503-14%$1.2B
#5
$654.8M1909N/AN/A

Insmed Incorporated Funding

DateAmountRoundLead InvestorsReference
2003-07-14$12.0MPrivate PlacementWells Fargo SecuritiesArticle
2005-03-16$35.0MUndisclosedMultipleArticle
2007-05-07$18.2MUndisclosedCE Unterberg TowbinArticle
2012-10-01$26.0MUndisclosedArticle
2013-07-18$62.4MUndisclosedLeerink Swann LLCArticle
2014-08-13$80.0MUndisclosedArticle
2015-04-01$194.0MUndisclosedArticle
2015-04-07$223.0MUndisclosedCitigroupArticle
2017-09-08$402.5MUndisclosedGoldman Sachs & Co. LLCArticle
2018-01-24$300.0MUndisclosedGoldman Sachs & Co. LLCArticle
2018-01-25$437.3MUndisclosedGoldman Sachs & Co. LLCArticle